Prof. Emile Voest

Prof. Emile Voest is one of the Netherlands' most distinguished oncologists, combining senior clinical responsibilities at the Netherlands Cancer Institute (NKI-AVL) in Amsterdam with internationally recognized research in translational oncology. The NKI-AVL—Antoni van Leeuwenhoek Hospital and the Netherlands Cancer Institute—is the country's only dedicated cancer center, consistently ranked among Europe's top oncological institutions for both clinical outcomes and research output. Prof. Voest's position at this institution places him at the cutting edge of cancer medicine, with access to biomarker-driven clinical trials, state-of-the-art molecular diagnostics, and a multidisciplinary environment uniquely suited to personalized cancer care.

With over 30 years in oncology, Prof. Voest has witnessed and contributed to the transformation of cancer treatment from a largely empirical discipline to one increasingly guided by the molecular characteristics of individual tumors. His clinical practice is centered on personalized oncology—using comprehensive genomic profiling, molecular tumor board discussions, and liquid biopsy technology to match patients with the treatment most likely to benefit their specific cancer, rather than applying population-level protocols.

He is particularly known for his pioneering work in circulating tumor DNA (ctDNA)—genetic material shed by tumors into the blood that can be detected and analyzed through a simple blood draw. ctDNA analysis allows earlier detection of disease recurrence, real-time monitoring of treatment response, and identification of resistance mechanisms as they emerge, without the need for repeat tissue biopsies. This work has significant practical implications for how patients with common cancers such as colorectal and breast cancer are monitored and treated.

Beyond his clinical work, Prof. Voest's laboratory research in organ-on-chip cancer models—miniaturized systems that recreate the tumor microenvironment—represents a frontier in understanding why some tumors resist therapy and how new drugs can be tested before reaching clinical trials.

Prof. Voest completed his medical degree (Geneeskunde) at Utrecht University, one of the Netherlands' premier research universities. He undertook his internal medicine and medical oncology training at Utrecht University Medical Center (UMC Utrecht), where he subsequently completed his PhD in cancer biology, focusing on tumor angiogenesis—the process by which tumors develop their own blood supply, which was a major research area in oncology at the time. His PhD work contributed to understanding how anti-angiogenic therapy could be used to starve tumors of nutrients. He was appointed as professor of medical oncology at Utrecht University before moving to the NKI-AVL to focus on translational precision oncology research and clinical care at the national cancer center. He has held visiting appointments at major international cancer research centers and has been a visiting professor at institutions across Europe and North America. He has supervised over 40 PhD students throughout his career.

Prof. Voest's clinical practice is organized around the principle that every advanced cancer patient's treatment should be informed by the molecular makeup of their tumor. He is a core member of the NKI-AVL Molecular Tumor Board—an expert panel that reviews genomic profiling results and recommends matched targeted therapies or clinical trials for patients whose tumors have specific genetic alterations. This approach is particularly valuable for patients with rare cancers or those who have exhausted standard treatment options.

For breast cancer, he manages hormone receptor-positive, HER2-positive, and triple-negative subtypes, applying endocrine therapies, CDK4/6 inhibitors, antibody-drug conjugates, and immunotherapy in accordance with molecular stratification. For colorectal and other gastrointestinal cancers, he applies KRAS/NRAS/BRAF-guided therapy selection and MSI-H immunotherapy. He uses liquid biopsy (ctDNA) routinely for disease monitoring, residual disease assessment, and resistance profiling. His access to clinical trials at the NKI-AVL—one of Europe's most active phase I/II oncology trial centers—means many of his patients have the option of receiving investigational treatments not yet available elsewhere.

Prof. Voest has an exceptionally prolific research career, with over 300 peer-reviewed publications in high-impact journals including Nature Medicine, Cancer Cell, the New England Journal of Medicine, and Nature Genetics. His most cited and internationally recognized research body concerns circulating tumor DNA (ctDNA) as a tool for cancer monitoring, response assessment, and resistance profiling. His studies demonstrated the ability of ctDNA to detect disease recurrence weeks to months before clinical or radiological evidence, opening new possibilities for adaptive treatment strategies.

His work on tumor-on-chip and organoid-based drug testing systems explores whether miniaturized models of patient tumors—grown in the laboratory using biopsy tissue—can predict clinical drug response, an approach that could transform how new cancer therapies are prioritized in drug development. He has been principal investigator on Dutch Cancer Society (KWF) and European Research Council (ERC) funded projects and has led major European consortium studies in precision oncology. He is a founding scientific contributor to the CPCT (Center for Personalized Cancer Treatment) initiative in the Netherlands, which performs whole-genome sequencing on metastatic cancers to identify actionable alterations.

The NKI-AVL regularly receives international patients seeking expert oncological opinion, access to clinical trials not available in their home country, or personalized treatment planning based on molecular tumor profiling. The institute has an international patient office with English-speaking staff, assistance with medical record and imaging transfer, and coordination with international health insurers. Prof. Voest consults in Dutch and English. EU patients may access care under EU cross-border healthcare provisions; non-EU patients are seen privately with transparent cost information. Video consultations are available for initial case review and second opinion discussions, making Prof. Voest's expertise accessible to patients anywhere who can share digital records, imaging, and molecular profiling reports electronically.

Prof. Voest received the Dutch Cancer Society (KWF) Research Pioneer Award, one of the Netherlands' highest oncology research honors, for his transformative work in liquid biopsy and personalized cancer medicine. He is an ESMO Fellow (FESMO), recognizing his European scientific leadership in medical oncology. The NKI-AVL honored him with its Distinguished Investigator Award for sustained excellence in translational cancer research. He is a member of the American Association for Cancer Research (AACR) and serves on the scientific advisory boards of several European cancer research consortia. He has been invited as a plenary or keynote speaker at ESMO, AACR, and ASCO annual meetings, and contributes to ESMO guideline panels on personalized oncology and biomarker testing. He is a frequent peer reviewer for Nature Medicine, Cancer Cell, and the New England Journal of Medicine.